TITLE

Monitoring of Antiretroviral Therapy and Mortality in HIV Programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study

AUTHOR(S)
Estill, Janne; Egger, Matthias; Johnson, Leigh F.; Gsponer, Thomas; Wandeler, Gilles; Davies, Mary-Ann; Boulle, Andrew; Wood, Robin; Garone, Daniela; Stringer, Jeffrey S. A.; Hallett, Timothy B.; Keiser, Olivia
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: Mortality in patients starting antiretroviral therapy (ART) is higher in Malawi and Zambia than in South Africa. We examined whether different monitoring of ART (viral load [VL] in South Africa and CD4 count in Malawi and Zambia) could explain this mortality difference. Design:: Mathematical modelling study based on data from ART programmes. Methods: We used a stochastic simulation model to study the effect of VL monitoring on mortality over 5 years. In baseline scenario A all parameters were identical between strategies except for more timely and complete detection of treatment failure with VL monitoring. Additional scenarios introduced delays in switching to second-line ART (scenario B) or higher virologic failure rates (due to worse adherence) when monitoring was based on CD4 counts only (scenario C). Results are presented as relative risks (RR) with 95% prediction intervals and percent of observed mortality difference explained. Results: RRs comparing VL with CD4 cell count monitoring were 0.94 (0.74–1.03) in scenario A, 0.94 (0.77–1.02) with delayed switching (scenario B) and 0.80 (0.44–1.07) when assuming a 3-times higher rate of failure (scenario C). The observed mortality at 3 years was 10.9% in Malawi and Zambia and 8.6% in South Africa (absolute difference 2.3%). The percentage of the mortality difference explained by VL monitoring ranged from 4% (scenario A) to 32% (scenarios B and C combined, assuming a 3-times higher failure rate). Eleven percent was explained by non-HIV related mortality. Conclusions: VL monitoring reduces mortality moderately when assuming improved adherence and decreased failure rates.
ACCESSION #
87625569

 

Related Articles

  • Scaling up stigma? The effects of antiretroviral roll-out on stigma and HIV testing. Early evidence from rural Tanzania. Roura, M.; Urassa, M.; Busza, J.; Mbata, D.; Wringe, A.; Zaba, B. // Sexually Transmitted Infections;Aug2009, Vol. 85 Issue 4, p18 

    Objective: To investigate the interplay between antiretroviral therapy (ART) scale-up, different types of stigma and Voluntary Counselling and Testing (VCT) uptake 2 years after the introduction of free ART in a rural ward of Tanzania. Methods: Qualitative study using in-depth interviews and...

  • PRO 140 - A Novel CCR5 Co-Receptor Inhibitor. Khatib, Nadia; Das, Satyajit // Recent Patents on Anti-Infective Drug Discovery;Jan2010, Vol. 5 Issue 1, p18 

    Despite an increase in the variety of anti-retroviral agents in the market, there remains a need for novel agents to treat HIV 1 infected individuals, in order to overcome existing problems with adherence, toxicities, drug interactions and viral resistance. In this article, we will describe Pro...

  • Human papillomavirus infection and disease in men: Impact of HIV. Delany-Moretlwe, S.; Chikandiwa, A.; J Gibbs, J. // Southern African Journal of HIV Medicine;Dec2013, Vol. 14 Issue 4, p183 

    There is growing evidence of a significant burden of human papillomavirus (HPV) infection and associated disease in men. High rates of HPV infection have been observed in men from sub-Saharan Africa where HIV prevalence is high. HIV infection increases HPV prevalence, incidence and persistence...

  • Multiple ART Programs Create a Dilemma for Providers to Monitor ARV Adherence in Uganda. Obua, Celestino; Gusdal, Annelie; Waako, Paul; Chalker, John C.; Tomson, Goran; Wahlström, Rolf // Open AIDS Journal;2011, Vol. 5, p17 

    Background: Increased availability and accessibility of antiretroviral therapy (ART) has improved the length and quality of life amongst people living with HIV/AIDS. This has changed the landscape for care from episodic to longterm care that requires more monitoring of adherence. This has led to...

  • Barriers to antiretroviral therapy adherence in rural Mozambique.  // BMC Public Health;2011, Vol. 11 Issue 1, p650 

    The article offers information on a study conducted by the authors on barriers to antiretroviral therapy (ART) adherence to treat HIV infection in Zambézia, Mozambique. It states that 76 women and 88 men were interviewed, out of which 40 were health care workers (HCWs). It mentions that HCWs...

  • The impact of highly active antiretroviral therapy on high-risk behaviour of HIV-infected patients in sub-Saharan Africa. Kabonge Kaye, Dan; Kakaire, Othman; Odongo Osinde, Michael; Chrysotom Lule, John; Kakande, Nelson // Journal of Infection in Developing Countries;Jun2013, Vol. 7 Issue 6, p436 

    Introduction: High-risk sexual behaviors such as multiple sexual partners, inconsistent condom use, acquisition of sexually transmitted infection (STIs), and non-use of contraceptives persist in HIV patients undergoing care. We conducted a systematic review of studies conducted in the era of...

  • The effect of sexually transmitted co-infections on HIV viral load amongst individuals on antiretroviral therapy: a systematic review and meta-analysis. Champredon, David; Bellan, Steven E.; Delva, Wim; Hunt, Spencer; Chyun-Fung Shi; Smieja, Marek; Dushoff, Jonathan // BMC Infectious Diseases;Aug2015, Vol. 15 Issue 1, p1 

    Background: Antiretroviral therapy (ART) markedly reduces HIV transmission, and testing and treatment programs have been advocated as a method for decreasing transmission at the population level. Little is known, however, about the extent to which sexually transmitted infections (STIs), which...

  • Adherence to antiretroviral therapy in pregnancy. Kingston, M. A.; Letham, C. J.; McQuillan, O. // International Journal of STD & AIDS;Nov2007, Vol. 18 Issue 11, p787 

    Successful interventions to prevent congenital HIV require adherence to highly active antiretroviral therapy (HAART) in pregnancy from mothers and agreement with other interventions including mode of delivery and infant testing. We sought to audit adherence support offered antenatally, adherence...

  • Does HAART Efficacy Translate to Effectiveness? Evidence for a Trial Effect Menezes, Prema; Miller, William C.; Wohl, David A.; Adimora, Adaora A.; Leone, Peter A.; Eron Jr., Joseph J. // PLoS Clinical Trials;Jul2011, Vol. 6 Issue 7, p1 

    Background: Patients who participate in clinical trials may experience better clinical outcomes than patients who initiate similar therapy within clinical care (trial effect), but no published studies have evaluated a trial effect in HIV clinical trials. Methods: To examine a trial effect...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics